SVR12 in the combined immediate treatment group and intensive pharmacokinetic population was 99 % ( 95 % CI 953-1000 ; 115/116 ) , with one relapse 12 weeks after end of treatment when compared with a historical control of 45 % , based on meta-analyses of interferon-based regimens used in clinical trials of patients infected with HCV who are on haemodialysis .